Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0663, etoricoxib · 6 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| MK0663, etoricoxib | DRUG | - |
| Comparator: celecoxib | DRUG | - |
| Comparators: ibuprofen and placebo | DRUG | - |
| Comparator: Diclofenac sodium | DRUG | - |
Inclusion Criteria: * Osteoarthritis of the knee or hip which requires treatment with a medication to obtain pain relief Exclusion Criteria: * Any known allergy to the study drugs
MK0663, also known as etoricoxib, is an investigational small molecule being studied for the treatment of rheumatoid arthritis and osteoarthritis. It is in Phase 3 clinical development for these musculoskeletal conditions. The drug is being developed by Organon & Co. (NYSE: OGN).
MK0663, or etoricoxib, is a small molecule that targets the COX-2 enzyme. By inhibiting COX-2, it is designed to reduce inflammation and pain associated with conditions like rheumatoid arthritis and osteoarthritis. This mechanism is the basis for its investigational use in these musculoskeletal disorders.
MK0663, also known as etoricoxib, is being developed by Organon & Co., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol OGN. The drug is currently in Phase 3 clinical trials for the treatment of rheumatoid arthritis and osteoarthritis.
MK0663, also known as etoricoxib, is in Phase 3 clinical development. It is an investigational drug being studied for rheumatoid arthritis and osteoarthritis, and it is not yet approved by regulatory authorities. Organon & Co. (NYSE: OGN) is the developer of this small molecule therapy.
MK0663, also known as etoricoxib, has completed four Phase 3 clinical trials for osteoarthritis. These include NCT00092703 with 6,000 patients, NCT00092755 with 548 patients, and NCT00092768 and NCT00092781, each with 500 patients. All trials were completed and involved adult patients aged 40 or 50 years and older.
Yes, MK0663 is the same as etoricoxib. The drug is known by both names, with MK0663 being the investigational code and etoricoxib the generic name. It is being developed by Organon & Co. (NYSE: OGN) for the treatment of rheumatoid arthritis and osteoarthritis.